###### Strengths and limitations of this study

This is the first study of Uyghur ethnic men to explore the association between apolipoprotein E (*APOE*) polymorphism and metabolic syndrome (MetS).The study was limited by lack of independent replication.The study lacks more detailed in-depth studies to confirm the link between *APOE* polymorphisms and MetS risk.

Introduction {#s1}
============

Metabolic syndrome (MetS) is characterised by a cluster of disorders that promotes atherosclerosis and increases the risk of cardiovascular diseases and diabetes mellitus,[@R1] for example: atherogenic dyslipidemia, insulin resistance and diabetes, hypertension, or abdominal obesity[@R2] and other diseases.[@R7]

The apolipoprotein E (*APOE*) gene, containing four exons and three introns, is mapped on the long arm of chromosome 19 (19q13.2).[@R11] There are three common alleles (*ε*2, *ε*3 and *ε*4); the *ε*3 allele is the most common and can be found in more than 80% of the general population, followed by *ε*4 and *ε*2.[@R12] [@R13]

*APOE* is a multifunctional protein found in all lipoproteins except for low-density lipoprotein cholesterol (LDL-C); it plays a critical role in lipoprotein metabolism.[@R14] Therefore, it is biologically possible for *APOE* to influence an individual's susceptibility to MetS, especially in terms of both triglyceride and cholesterol levels, which are major complications of MetS.[@R17] The altered expression or genetic polymorphism of *APOE* is considered as a risk factor for MetS.[@R18] [@R19] Although the possible association of *APOE* with the risk of MetS has been widely investigated in different populations,[@R20] MetS still remains under-represented in the Xinjiang population, especially in the Uyghur ethnic group. Our previous study found that in the Uyghur ethnic population, there is a tendency of higher frequency of the clustering of MetS.[@R23] Thus, this is the first study in terms of the distribution of *APOE* genetic polymorphisms and their association with metabolic profiles in patients with MetS, aimed at identifying possible genetic markers for this disease in this special population.

Methods and materials {#s2}
=====================

Participants and study design {#s2a}
-----------------------------

This case control study recruited 992 participants who were selected from the Affiliated Hospitals of Xinjiang Medical University Urumqi China. These participants were all Uyghur men who resided in the Xinjiang area, 482 with MetS, whereas the age-matched healthy control subjects had no history of MetS. All of the participants were fully informed of the purpose of this study, and every participant provided written informed consent before enrolment in the study.

Data collection and blood tests {#s2b}
-------------------------------

A questionnaire was used to collect data on the demographic, lifestyle and disease histories from all of the participants. A physical examination was also performed on every participant, including taking measurements of height (measured in centimetres with an error of \<0.5 cm), body weight (measured in kilograms with an error of \<0.1 kg), body mass index (BMI), waist circumference (WC) and hip circumference (calibrated weekly to within 1 mm using a plastic tape). The WC was measured at the end of a gentle expiration midway between the lowest rib and the iliac crest with the study participant standing, while the hip circumference was measured at the greater trochanter. The waist-to-hip ratio was determined as the WC (cm) divided by the hip circumference (cm). Blood pressure was measured using an automatic clinical blood pressure monitor three times in the sitting position following a standard protocol. All of the participants were at rest for at least 10 min before the physical examination.

All of the participants were also asked to fast for at least 12 h and to not consume any alcohol or high-fat foods the night before blood withdrawal. Two millilitres of venous blood was collected from each participant to assess the serum triglyceride and cholesterol, high-density lipoprotein cholesterol (HDL-C), LDL-C and fasting plasma glucose levels as measured using the 7060 Automatic Biochemical Analyzer (Hitachi, Ltd, Tokyo, Japan). All of the laboratory analyses were performed in the same certified laboratory. Quality control measures were followed for the estimation of all the variables.

Standard of diagnosis {#s2c}
---------------------

The participants were divided into two groups based on affliction with MetS. The diagnostic criteria for MetS were according to the 2005 National Cholesterol Education Program Adult Treatment Panel ΙΙΙ,[@R26] the 2005 International Diabetes Federation,[@R27] the 2004 Chinese Diabetes Society[@R28] and the 2007 Joint Committee for Developing Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults definitions,[@R29] meeting at least three of the following criteria: (1) abdominal obesity (WC\>90 cm for men; (2) triglyceride level ≥1.7 mmol/L; (3) reduced HDL-C levels \<0.9 mmol/L in men; (4) raised systolic or diastolic blood pressure (DBP) of 140/90 mm Hg or higher or previously diagnosed hypertension; (5) raised fasting plasma glucose level of 6.1 mmol/L or higher or previously diagnosed type 2 diabetes mellitus.

Genomic DNA extraction and *APOE* genotyping {#s2d}
--------------------------------------------

The detailed method of genomic DNA extraction and *APOE* genotyping was performed as described previously.[@R30]

Statistical analysis {#s2e}
--------------------

The data were summarised as numbers, percentages or means±SDs; organised in EpiData 3.0 software (The EpiData Association, Odense, Denmark); and analysed using the SPSS V.16.0 for Windows software package (SPSS, Chicago, Illinois, USA). Simple descriptive statistics were used to describe the variables among the participants. The differences in the measurements from different groups were compared with Student t test and a one-way analysis of variance. The *APOE* genotypes and frequencies were analysed with Pearson's χ^2^ test if the genotypes met the Hardy-Weinberg equilibrium. A p value of \<0.05 was considered statistically significant.

Results {#s3}
=======

Characterisation of the study population {#s3a}
----------------------------------------

The summary statistics of the study population are shown in [table 1](#BMJOPEN2015010049TB1){ref-type="table"}. The data indicate that, except for age and LDL-C, other quantitative variables were statistically significant (p\<0.05), and except for the HDL-C level, the other quantitative variables in the MetS group were higher than those in the non-MetS group ([table 1](#BMJOPEN2015010049TB1){ref-type="table"}).

###### 

Comparison of the quantitative variables between the MetS and non-MetS groups

  Variable(s)             Non-MetS group (510)   MetS group (482)   p Value
  ----------------------- ---------------------- ------------------ ----------
  Age (years)             46.77±13.27            47.54±11.83        0.0680
  BMI (kg/m^2^)           26.52±4.11             28.16±3.15         \<0.0001
  Waistline (cm)          92.79±10.65            98.43±9.08         \<0.0001
  SBP (mm Hg)             120.61±12.26           126.92±14.64       \<0.0001
  DBP (mm Hg)             85.33±13.78            96.62±12.10        \<0.0001
  FPG (mmol/L)            5.01±1.13              5.59±1.77          \<0.0001
  Triglyceride (mmol/L)   1.97±1.45              3.26±1.65          \<0.0001
  TC (mmol/L)             4.37±1.27              4.06±1.60          0.0010
  HDL-C (mmol/L)          1.23±0.53              1.10±0.51          \<0.0001
  LDL-C (mmol/L)          2.67±0.86              2.74±0.78          0.1920

Data are shown as mean±SD.

The Mann-Whitney U test was used to analyse the differences in the quantitative variables between the MetS and non-MetS groups.

BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; SBP, systolic blood pressure; TC, total cholesterol.

Comparison of the *APOE* allele frequencies and genotype distribution in the MetS group with those of the control group {#s3b}
-----------------------------------------------------------------------------------------------------------------------

The allele and genotype distributions of the *APOE* polymorphisms are presented in [table 2](#BMJOPEN2015010049TB2){ref-type="table"}. There was no evidence of significant deviation from the Hardy-Weinberg equilibrium in any distribution. The frequencies of the *APOE* alleles *ε*2, *ε*3 and *ε*4 in Uyghur men were 8.5%, 80.0% and 11.5%, respectively, and the frequencies of different *APOE* alleles and genotypes between the MetS and non-MetS groups were different (p\<0.05). In the MetS group, the frequencies of the *APOE ε*2 and *ε*4 alleles were lower, and the frequencies of the *ε2/2, ε2/3 and ε2/4* genotypes were significantly lower (p\<0.05) than those in the non-MetS group ([table 2](#BMJOPEN2015010049TB2){ref-type="table"}).

###### 

Genotype and allele distributions of the *APOE* in the MetS and non-MetS groups

                Total (992)    Non-MetS group (510)   MetS group (482)
  ------------- -------------- ---------------------- ------------------
  Genotype                                            
   ε2/2         25 (2.5%)      20 (3.9%)              5 (1.0%)
   ε2/3         105 (10.6%)    66 (12.9%)             39 (8.1%)
   ε2/4         14 (1.4%)      11 (2.2%)              3 (0.6%)
   ε3/3         712 (71.8%)    332 (65.1%)            380 (78.8%)
   ε3/4         59 (5.9%)      32 (6.3%)              27 (5.6%)
   ε4/4         77 (7.8%)      49 (9.6%)              28 (5.8%)
   χ^2^ Value   --             29.1                   
   p Value      --             \<0.0001               
  Allele                                              
   ε2           169 (8.5%)     117 (11.5%)            52 (5.4%)
   ε3           1588 (80.0%)   762 (74.9%)            826 (85.5%)
   ε4           227 (11.5%)    139 (13.7%)            88 (9.1%)
   χ^2^ Value   --             37.7                   
   p Value      --             \<0.0001               

Data are shown as n (%). Pearson's χ^2^ test was used to analyse the differences of *APOE* (genotype or allele) between the MetS and non-MetS groups.

MetS, metabolic syndrome.

Comparison of the means of anthropometric, biochemical and clinical parameters between different *APOE* genotypes in the two groups {#s3c}
-----------------------------------------------------------------------------------------------------------------------------------

To evaluate the effect of the *APOE* genotype and the anthropometric, biochemical and clinical parameters, the participants in our study were subdivided into three groups: (1) *ε*3/*ε*3 participants (*APOE*3 group), (2) participants carrying *ε*2/*ε*2 or *ε*2/*ε*3 genotypes (*ε*2 carriers, *APOE*2 group) and (3) participants carrying *ε*4/*ε*4 or *ε*3/*ε*4 (ε4 carriers, *APOE*4 group). The participants with the *ε*2/*ε*4 genotype (n=14) were excluded from this analysis because of the opposite effects of the *ε*2 and *ε*4 alleles on the lipid levels.

In the MetS groups, none of the parameters had significant associations when comparing *ε*3 allele carriers with *ε*4 allele carriers, in contrast to the comparison of *ε*2 allele carriers with *ε*3 allele carriers. In the non-MetS group, the BMI, waistline, DBP and LDL-C in the *ε*2 allele carriers were lower (p\<0.05) than those in the *ε*3 allele carriers). In contrast, the *ε*4 allele carriers had significantly higher means of these parameters than the *ε*2 allele carriers ([table 3](#BMJOPEN2015010049TB3){ref-type="table"}).

###### 

Comparison of the anthropometric, biochemical and clinical parameters among different *APOE* genotypes in the two groups (mean±SD)

                          Non-MetS group   MetS group                                                                                                                           
  ----------------------- ---------------- -------------- -------------- -------------- --------- --------- -------------- -------------- -------------- -------------- ------- -------
  BMI (kg/m^2^)           26.48±4.09       25.52±3.36     26.76±4.44     26.37±3.02     0.012\*   0.439     28.15±3.14     28.11±3.36     28.13±3.16     28.33±2.87     0.973   0.666
  Waistline (cm)          92.71±10.55      90.59±10.90    93.12±10.79    93.28±8.92     0.048\*   0.898     98.31±8.93     100.88±14.90   98.22±8.22     96.93±6.88     0.061   0.318
  SBP (mm Hg)             120.81±12.27     118.66±14.02   120.65±11.46   123.70±13.05   0.178     0.044\*   126.55±14.59   129.50±25.14   126.16±12.19   129.51±17.17   0.147   0.108
  DBP (mm Hg)             85.52±13.82      82.44±13.51    85.81±13.78    87.56±13.40    0.043\*   0.308     96.74±12.04    95.59±18.34    96.75±11.10    97.55±12.18    0.545   0.649
  FPG (mmol/L)            5.00±1.14        5.16±1.79      4.96±0.81      5.00±1.38      0.145     0.787     5.58±1.75      5.67±1.21      5.58±1.80      5.46±1.77      0.761   0.623
  Triglyceride (mmol/L)   1.94±1.39        1.71±1.00      2.02±1.49      1.85±1.32      0.065     0.329     3.26±1.65      3.27±1.50      3.25±1.71      3.37±1.34      0.928   0.579
  TC (mmol/L)             4.34±1.25        4.19±1.18      4.31±1.26      4.61±1.25      0.404     0.063     4.05±1.60      4.25±1.84      4.05±1.58      3.90±1.54      0.449   0.504
  HDL-C (mmol/L)          1.23±0.52        1.17±0.43      1.23±0.53      1.25±0.57      0.284     0.733     1.10±0.51      1.18±0.89      1.10±0.47      1.05±0.33      0.333   0.483
  LDL-C (mmol/L)          2.68±0.86        2.29±0.82      2.74±0.85      2.86±0.81      0.000\*   0.230     2.74±0.79      2.64±0.62      2.78±0.80      2.58±0.83      0.263   0.691

A t test was used to analyse the differences in parameters among different *APOE* genotypes.

P^a^: p values that were obtained when comparing *APOE2* participants with *APOE3* participant.

P^b^: p values that were obtained when comparing *APOE3* participants with *APOE4* participants*.* (1) *APOE*3 group: participants carrying the *ε*3/*ε*3 genotype; (2) *APOE2* group: participants carrying the *ε*2/*ε*2 or *ε*2/*ε*3 genotype; (3) *APOE4* group: participants carrying the *ε*4/*ε*4 or *ε*3/*ε*4 genotype. Participants with the *ε*2/*ε*4 genotype (n=14) were excluded from the extra analyses because of the opposite effects of the *ε*2 and *ε*4 alleles on the lipid levels.

\*The mean difference was significant at the 0.05 level.

BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MetS: metabolic syndrome; SBP, systolic blood pressure; TC, total cholesterol.

The prevalence of MetS and the individual components of dyslipidemia between the *APOE2* and *APOE4* groups {#s3d}
-----------------------------------------------------------------------------------------------------------

By evaluating the effects of MetS and the individual components of dyslipidemia between the *APOE2* and *APOE4* groups, we found that the prevalence of MetS, abdominal obesity, high blood pressure, hypertriglyceridaemia and hypercholesterolaemia were lower in the *APOE2* group (p\<0.05); the prevalence of hyperglycaemia and low HDL-C was higher in the *APOE2* group but had no significant association (p\>0.05) ([table 4](#BMJOPEN2015010049TB4){ref-type="table"}).

###### 

The prevalence of MetS and the individual components of dyslipidemia between the *APOE*2 and *APOE*4 groups

                                     *APOE2*          *APOE4*          OR (95% CI)              p Value
  ---------------------------------- ---------------- ---------------- ------------------------ ---------
  n                                  130              136              --                       --
  MetS (no/yes)                      86/44 (33.8%)    81/55 (40.4%)    1.327 (0.806 to 2.186)   0.266
  Abdominal obesity (no/yes)\*       46/84 (64.6%)    32/104 (76.5%)   1.78 (1.042 to 3.039)    0.034
  Hypertension (no/yes)\*            67/63 (48.5%)    49/87 (64.0%)    1.888 (1.156 to 3.085)   0.011
  Hypertriglyceridaemia (no/yes)     61/69 (53.1%)    52/84 (61.8%)    1.428 (0.877 to 2.327)   0.152
  Hypercholesterolaemia (no/yes)\*   120/10 (7.7%)    112/24 (17.6%)   2.571 (1.177 to 5.617)   0.015
  Hyperglycaemia (no/yes)            114/16 (12.3%)   125/11 (8.1%)    0.627 (0.299 to 1.407)   0.255
  Low HDL-C (no/yes)                 103/27 (13.6%)   115/21 (10.6%)   0.697 (0.371 to 1.307)   0.259

Pearson's χ^2^ test was used to analyse the differences.

Power by YOZOSOFT.

\*The mean difference was significant at the 0.05 level.

HDL-C, high-density lipoprotein cholesterol; MetS, metabolic syndrome.

Discussion {#s4}
==========

The *APOE* genotypes and allele distributions vary among different races and geographic areas.[@R34] In this study, we found that the general distribution of *APOE* allele E3 in Uyghur men was 80.0%, which is between the distributions reported in the Han Chinese and Caucasian populations. Our data indicated that the Uyghurs had a different allele distribution from the Han Chinese and Caucasians, prompting a different genetic background of the Uyghur. Indeed, an earlier study which was aimed at identifying the origin of human species applying DNA sequencing technology to have analysed a Uyghur mummy that was unearthed 3000 years ago from a dry desert in the Tarim basin of Xinjiang, China, has demonstrated that the Uyghur ethnic group currently living in Xinjiang, China originated from Europe.[@R35] Our current data of the *APOE* polymorphism may provide additional evidence for this finding. However, after approximately 3000 years of evolution, one may expect that the *APOE*3 allele may have changed. We previously demonstrated that the MetS prevalence was higher in the Uyghur ethnic group.[@R36] [@R37] This ethnic group has a different genetic background, diet and lifestyle; furthermore, these people live in a special area in China, with a unique environment and natural conditions, and their population is relatively stable.

Our study found that the frequencies of the *APOE* alleles *ε*2, *ε*3 and ε4 in Uyghur men were 8.5%, 80.0% and 11.5%, respectively; that the frequencies of the *APOE ε*2 and *ε*4 alleles were lower in the MetS group than in the non-MetS group; and that the *ε2/2, ε2/3* and *ε2/4* genotype frequencies were clearly lower in the MetS group than in the non-MetS group (p\<0.05). The frequency of the *ε*2/2 genotype was higher in the MetS group than the frequency of the ε4/4 genotype in the control subjects, but in patients with MetS, the *ε*2/2 carrier frequency was lower than that of *ε*4/4. Variations in the genetic structures in different populations are possible, but differences in testing methods should also be considered. The frequency of *APOE*2 was lower in the MetS group than in the non-MetS group. The *APOE*2 genotype carriers had the lowest HDL-C and LDL-C levels. The mechanism of this effect is most likely due to decreased conversion of the very low-density lipoprotein (VLDL) into LDL-C as observed in *ε2* carriers.[@R38] Thus, a high frequency of the *ε2* allele would appear to predict a favourable lipid profile, indicating that *APOE*2 may be a protective factor against MetS.

Many studies have suggested that variation in the *APOE* gene is associated with the lipid levels.[@R16] [@R39] [@R40] We found that the triglyceride and LDL-C levels were lower in the *ε*2 allele carriers than in the *ε*3 allele carriers. In contrast, the *ε*4 allele carriers had significantly higher means of these plasma lipid levels than did the *ε*2 and *ε*3 allele carriers. The prevalence of abdominal obesity, high blood pressure, hypertriglyceridaemia and hypercholesterolaemia was lower in the *APOE*2 group than in the *APOE*4 group. The risks of these individuals with *ε*4 allele gene carriers for getting these changes were 1.327, 1.780, 1.888, 1.428 and 2.571 times greater than the risks of those with *ε*2 allele gene carriers.

Some limitations of this study should be considered. Since we only genotyped the *APOE* gene of the participants, and could not do population stratification analyses, we could not ensure whether there were biases due to confounding by ancestry or not. However, since all the participants were recruited from the same geographic region and reported to be Uyghur, the issue of population stratification should be limited in the current study. Besides, although we found that *APOE* alleles were associated with MetS risk for Uyghur men residing in the Xinjiang area, studies in a larger sample or other population to replicate this result are urged.

In conclusion, the distribution of the *APOE* alleles and genotype frequencies in Uyghur men is unique and is associated with MetS risk. *APOE*4 is associated with hypertriglyceridaemia, with a slightly increased risk for MetS, but *APOE*2 is associated with protection against MetS in Uyghur males in China. However, this study is an initial step in understanding the relationship between *APOE* gene polymorphisms and MetS in Uyghur men, and more detailed in-depth studies in the future are needed to confirm the link between *APOE* polymorphisms and MetS risk.
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